Articles
Study Results

Retatrutide Long-Term Safety and Effects: What the Longest Trials Show

Retatrutide has been studied for up to 80 weeks in Phase 3 and 104 weeks in a selected group. The safety numbers from those trials, and what is still unknown.

Written By
retaweightloss.com
Updated on
11 Nov 2026
Time to read
5 min read
Category
Study Results
Retatrutide long-term safety and effects: what the longest trials show

Retatrutide Long-Term Safety and Effects: What the Longest Trials Show

Retatrutide has been studied for up to 80 weeks in Phase 3 and 104 weeks in a selected group. The safety numbers from those trials, and what is still unknown.

By
RetaWeightLoss.com
Created on:
31 Jan 2026
Updated on:
11 Nov 2026
Share this post

Retatrutide Long-Term Safety: The Short Answer

The longest data so far cover up to 80 weeks of treatment in Phase 3 trials, with about 4,300 people on retatrutide across the five placebo-controlled trials, and weight data to 104 weeks in a selected group of 532 TRIUMPH-1 participants, 423 of whom had been on retatrutide from the start. In TRIUMPH-1, the largest trial, published in full in September 2026 and updated in October, the 80-week safety numbers on the highest dose, 12 mg, were:

  • Serious adverse events: 10.5% of participants, against 5.5% on placebo.
  • Stopped because of adverse events: 11.2%, against 4.6% on placebo.
  • Low blood pressure: 8.8%, against 0.9% on placebo, mostly mild or moderate.
  • Most common side effects: gastrointestinal, with nausea in 42.4% against 14.8% on placebo, mostly while the dose was being increased.

In TRIUMPH-3, in people with established heart disease, major cardiovascular events were too few to show a difference from placebo either way (27 against 23). What happens over five or ten years, how often rare side effects occur, and whether retatrutide reduces heart attacks and strokes are not yet known; a dedicated outcomes trial with an enrollment goal of 10,000 people is due to run until 2029.

How Long Has Retatrutide Been Studied?

TrialWho took partParticipantsLengthResults so far
Phase 2 obesity trial Obesity or overweight, without diabetes 338 48 weeks Published in full, 2023
TRIUMPH-1 Obesity or overweight, without diabetes 2,339 80 weeks Lilly announcement, May 2026; published in full, September 2026
TRIUMPH-1 extension BMI 35+ at screening, still on their assigned dose at week 80 (including 109 from the placebo group) 532 104 weeks in total Lilly announcement, May 2026; weight results in the published paper
TRIUMPH-2 Obesity or overweight, with type 2 diabetes 1,152 80 weeks Lilly announcement, July 2026; published in full, September 2026
TRIUMPH-3 Severe obesity (BMI 35+), with cardiovascular disease 1,949 80 weeks Lilly announcement, July 2026
TRIUMPH-4 Obesity or overweight, with knee osteoarthritis 445 68 weeks Lilly announcement, December 2025
TRANSCEND-T2D-1 Type 2 diabetes inadequately controlled by diet and exercise 537 40 weeks Published in full, June 2026
TRANSCEND-T2D-2 Type 2 diabetes on metformin, with or without an SGLT2 inhibitor; open-label comparison with semaglutide 2 mg, no placebo 1,298 80 weeks Lilly announcement, October 2026
TRIUMPH-Outcomes Age 45+, BMI 27+, with atherosclerotic cardiovascular disease and/or chronic kidney disease Goal of 10,000 Expected to finish February 2029 Ongoing


Based on how each trial was randomized, roughly 4,300 people received retatrutide across the five placebo-controlled Phase 3 trials with results so far; a sixth, TRANSCEND-T2D-2, randomized another 1,298 people to retatrutide or semaglutide. That is enough to measure common side effects well, but trials of a few thousand people cannot reliably detect side effects that affect only one person in several thousand. Those usually come to light only after a drug has been used much more widely.

What the Longest Data Show

The published TRIUMPH-1 paper reports that 532 participants continued into a 24-week extension. According to its supplementary appendix, they needed to have had a BMI of 35 or more at screening, to be on their assigned dose at week 80 and to have a BMI above 22 at that point; 109 came from the placebo group. In the extension, all took retatrutide at the highest dose they tolerated, 9 mg or 12 mg. Those originally assigned to 12 mg reached an average weight loss of 30.3% at 104 weeks if taken as intended, or 29.9% counting everyone in that group. We found no side effects reported separately for the extension in Lilly's announcement, the paper or its appendix, and because the group was selected, it cannot show how everyone in the trial would have fared.

In the Phase 3 trials, the most common adverse events were gastrointestinal. The share who stopped because of adverse events at 12 mg was 11.2% in TRIUMPH-1 (4.6% on placebo), according to the published paper, 7.7% in TRIUMPH-2 (4.9%) and 13.5% in TRIUMPH-3 (4.8%), all over 80 weeks, and 18.2% in the 68-week TRIUMPH-4 (4.0%), where Lilly said the rates were highly correlated with baseline BMI and included people who stopped because of perceived excessive weight loss. In TRANSCEND-T2D-2, an open-label comparison with semaglutide 2 mg over 80 weeks, 7.9% stopped because of adverse events on 12 mg (4.8% on 9 mg) against 2.7% on semaglutide.

The full TRIUMPH-1 paper gives the most complete safety picture so far for 80 weeks of treatment. Serious adverse events occurred in 7.7%, 7.7% and 10.5% of participants on 4 mg, 9 mg and 12 mg, against 5.5% on placebo. Low blood pressure was reported in 8.8% of participants on 12 mg against 0.9% on placebo, more often in people also taking blood pressure medicines, and was mostly mild or moderate. Urinary tract infections were reported in 7.5% to 8.7% of participants on retatrutide against 5.3% on placebo, 92% of them in women (see retatrutide and urinary tract infections), and severe or serious acute kidney events in two participants each on 4 mg and 12 mg and none on placebo (see retatrutide and kidney function). Pancreatitis confirmed by adjudication occurred in 8 participants on retatrutide and 2 on placebo, numbers the investigators said were too small for conclusions about a treatment effect, although average pancreatic enzyme levels rose on retatrutide (by about 20% to 31%, against 5% to 6% on placebo), with the averages remaining within the normal range, according to the supplementary appendix; severe or serious gallbladder or biliary disorders in 0.7% to 1.7% of participants on retatrutide, depending on the dose, and 0.7% on placebo; and cancer in 0.9% to 2.1%, against 1.0% on placebo. Thyroid cancer was reported in one participant each on 4 mg and 12 mg and none on placebo; the paper notes that neither was medullary thyroid cancer and that there was no C-cell hyperplasia. Three participants on 12 mg had severe or serious liver disorders: acute cholestatic hepatitis A, acute ischemic hepatitis most likely due to dehydration, and raised liver enzymes associated with worsening gallstone disease. Four participants on retatrutide and two on placebo died; one death, in a participant with known heart failure 189 days after stopping retatrutide, was adjudicated as cardiovascular.

TRIUMPH-3, in 1,949 people with a BMI of 35 or more and established cardiovascular disease, is the only Phase 3 announcement to report cardiovascular events. There were 27 major cardiovascular events — cardiovascular death, heart attack or stroke — among participants randomized to retatrutide and 23 among those randomized to placebo, a hazard ratio of 1.12 (95% confidence interval 0.64 to 1.96); on a broader measure that also counts death from any cause, heart failure events and coronary revascularization, there were 44 and 52 (hazard ratio 0.82, 0.55 to 1.22). The company said such events occurred less often than anticipated in both groups. With this few events, the results cannot show whether retatrutide raises or lowers cardiovascular risk. The TRIUMPH-1 paper also reports major cardiovascular events confirmed by adjudication, in 0.2% to 0.9% of participants on retatrutide, depending on the dose, and 0.2% on placebo; its investigators wrote that the trial was not powered to assess cardiovascular safety.

The 48-week Phase 2 obesity trial, published in full in 2023, found serious adverse events in 4% of participants on both retatrutide and placebo. One participant on 12 mg had acute pancreatitis and three on retatrutide had gallbladder events, and heart rate rose with the dose, peaking at 24 weeks and declining after that.

Warnings on Related Approved Drugs

Retatrutide has no label yet, so it has no official list of warnings. The approved drugs closest to it, semaglutide and tirzepatide, carry these on their US labels. An FDA review would decide which, if any, apply to retatrutide:

  • Thyroid C-cell tumors. A boxed warning: both drugs cause these tumors in rodents, and whether they do in humans is unknown (see retatrutide and thyroid cancer risk). Both are contraindicated for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.
  • Acute pancreatitis and acute gallbladder disease.
  • Low blood sugar, particularly in people with type 2 diabetes who also take insulin or medicines that increase insulin release.
  • Acute kidney injury from dehydration, and severe gastrointestinal reactions.
  • Diabetic retinopathy complications in people with type 2 diabetes.
  • Hypersensitivity reactions and pulmonary aspiration during general anesthesia or deep sedation.
  • Heart rate increase, a separate warning on semaglutide's label.

What Happens After Stopping Retatrutide?

Neither Lilly nor the published TRIUMPH-1 paper has reported what happens to weight after people stop retatrutide. The closest evidence comes from tirzepatide. In the SURMOUNT-4 trial, participants took tirzepatide for 36 weeks and were then assigned either to continue or to switch to placebo for a year. Counting everyone assigned to placebo, they regained an average of 14.0% of their body weight over that year (14.8% among those who kept taking their assigned treatment as intended). The company also reported that 13.5% of them kept at least 80% of the weight they had lost, against 93.4% of those who continued.

That is a different drug, and whether retatrutide behaves the same way has not been tested in a reported trial. The evidence on stopping is covered in more detail in weight regain after stopping retatrutide.

What Is Still Unknown

  • Safety beyond two years. No reported trial has followed people on retatrutide for longer than 104 weeks.
  • Rare side effects, which trials of a few thousand people cannot measure reliably.
  • Cardiovascular outcomes. TRIUMPH-Outcomes, which is testing whether retatrutide lowers serious heart-related complications or prevents worsening kidney function, is expected to finish in February 2029.
  • The course of dysesthesia. The company said the majority of cases resolved during treatment in most of its trials, but neither its announcements nor the TRIUMPH-1 paper say how long they lasted or what happened after people stopped.
  • Weight after stopping retatrutide, and whether its effect holds over many years.

Why This Page Has No Monitoring Schedule

Some articles on this topic list tests to have, contraindications to observe and ways to taper the dose. This one does not. Retatrutide has no approved label, so there is no approved monitoring schedule, contraindication list or way of stopping it; for approved drugs, those come from the label and the prescriber.

Lilly's retatrutide page says it is not on the market and that no one can legally sell it for human use; in August 2026 the company said that, besides its clinical trials, it would make it available to a limited number of patients who meet specific medical criteria and cannot join a trial. It warns that illicit products "may contain unknown ingredients, harmful contaminants and impurities." Nothing in the trial data describes what taking them for months or years might do.

Retatrutide Long-Term Safety in Summary

Retatrutide's safety has been studied for up to 80 weeks in Phase 3; weight results, but no separate safety data, extend to 104 weeks in a selected group. In that time the common side effects were gastrointestinal; in the fully published TRIUMPH-1 trial, serious adverse events (10.5% against 5.5%) and low blood pressure (8.8% against 0.9%) were more common on the highest dose than on placebo; and cardiovascular events in people with heart disease were too few to show a difference either way. What happens over many years, how often rare side effects occur and what happens after stopping are not yet known; the TRIUMPH-Outcomes trial, expected to finish in 2029, is the next major source of long-term data.

Sources

  • Eli Lilly. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026.
  • Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
  • Eli Lilly. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025.
  • Eli Lilly. Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. March 19, 2026.
  • Eli Lilly. Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications. June 6, 2026.
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026; updated October 22, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Supplementary Appendix, Figure S1 and Tables S4 and S12. N Engl J Med. 2026.
  • Eli Lilly. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial. October 28, 2026. (TRANSCEND-T2D-2)
  • Eli Lilly. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. September 29, 2026.
  • Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.
  • Lilly Trials. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults (TRIUMPH-Outcomes). NCT06383390, trial listing.
  • Novo Nordisk. Wegovy (semaglutide) US prescribing information, boxed warning and section 5. Revised June 2026.
  • Eli Lilly. US prescribing information for tirzepatide for weight reduction, boxed warning and section 5. Revised August 2026.
  • Eli Lilly. SURMOUNT-4 results announcement (tirzepatide). December 11, 2023.
  • Eli Lilly. What to know about retatrutide.
  • STAT. Eli Lilly to allow more patients to apply for special access to unapproved obesity drug. August 3, 2026.

Medical Disclaimer: This article is for informational purposes only and is not medical advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and Lilly says no one can legally sell it for human use. Nothing here is a recommendation to use, seek out or avoid any medication.

Frequently asked questions

Is retatrutide safe long term?

That is not known yet. The longest data cover 80 weeks in Phase 3. In TRIUMPH-1, serious adverse events occurred in 10.5% of participants on 12 mg against 5.5% on placebo, and 11.2% stopped because of adverse events against 4.6%. Safety beyond about two years, rare side effects and cardiovascular outcomes are still being studied.

What are the long-term side effects of retatrutide?

None has been established beyond 80 weeks. Over that time the most common side effects were gastrointestinal, along with dysesthesia, urinary tract infections and, in TRIUMPH-1, low blood pressure (8.8% on 12 mg against 0.9% on placebo). Related approved drugs carry label warnings about thyroid C-cell tumors in rodents, pancreatitis and gallbladder disease.

Can retatrutide be taken long term?

Retatrutide is not approved, so there is no approved long-term use. In the trials, people took it for up to 80 weeks, and a selected group for up to 104 weeks. The TRIUMPH-Outcomes trial, with an enrollment goal of 10,000 people, is expected to finish in February 2029 and to add longer-term data.

How long has retatrutide been tested in trials?

Up to 80 weeks in the placebo-controlled Phase 3 trials reported so far, which included about 4,300 people on retatrutide, and 104 weeks for 423 of a selected group of 532 TRIUMPH-1 participants who had a BMI of 35 or more at the start and were still on their assigned dose at 80 weeks; the other 109 had been on placebo and took retatrutide only in the final 24 weeks. The earlier Phase 2 obesity trial lasted 48 weeks. No reported trial has gone beyond two years.

Newsletter

Stay Updated on New Articles & Research

Get notified when we publish new articles, research, and insights on obesity and weight loss.
You're subscribed!
You'll get new coverage as it's published.
Oops! Something went wrong while submitting the form.